# Paricalcitol, Fluorouracil, and Radiation Therapy in Treating Patients With Rectal Cancer That Can Be Removed in Surgery

> **NCT01197664** · PHASE1 · TERMINATED · sponsor: **Wake Forest University Health Sciences** · enrollment: 2 (actual)

## Conditions studied

- Mucinous Adenocarcinoma of the Rectum
- Stage IIA Rectal Cancer
- Stage IIB Rectal Cancer
- Stage IIC Rectal Cancer
- Stage IIIB Rectal Cancer
- Stage IIIC Rectal Cancer

## Interventions

- **DRUG:** paricalcitol
- **RADIATION:** radiation therapy
- **OTHER:** laboratory biomarker analysis
- **DRUG:** fluorouracil

## Key facts

- **NCT ID:** NCT01197664
- **Lead sponsor:** Wake Forest University Health Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-08
- **Primary completion:** 2012-07
- **Final completion:** 2014-04
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** Study terminated due to funding issues
- **Last updated:** 2018-07-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01197664

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01197664, "Paricalcitol, Fluorouracil, and Radiation Therapy in Treating Patients With Rectal Cancer That Can Be Removed in Surgery". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01197664. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*